Pharma BD Deal Intelligence
A $624M bet on Parkinson's rescue therapy that took four years and a CRL to reach market, then was written down $406M and pulled from the US/Canada within three years of launch
Full analysis, sources & comparables →GEN framed the 120% premium as well-aligned with Sunovion's CNS focus, citing FDA Fast Track designation just two days prior and the Q4 2016 Phase 3…
We believe that APL-130277 is a novel late-stage candidate with the potential to make a real difference for patients and their families... well-aligned with…
BMO Capital's Do Kim called APL-130277 a potential market redefiner with $2B worldwide peak sales potential; Zacks' Anita Dushyanth flagged the user-friendly…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sunovion (Sumitomo Dainippon's U.S. subsidiary) agreed to acquire Cynapsus Therapeutics for $40.50/share cash, ~$624M total (~120% premium). Lead asset APL-130277, a Phase 3 sublingual apomorphine film for off-episodes in Parkinson's disease. Closed October 24, 2016. Approved as Kynmobi in 2020 (since discontinued).
A $624M bet on Parkinson's rescue therapy that took four years and a CRL to reach market, then was written down $406M and pulled from the US/Canada within three years of launch
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc. (this deal) | 2016 | $624M | 28 |
| Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. | 2016 | $780M | 24 |
| Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd. | 2021 | $270M | — |
| Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) | 2019 | $3.0B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2016 deals · Sumitomo Dainippon Pharma Co., Ltd. deals · Neurology deals